Document Detail


The continual reassessment method in cancer phase I clinical trials: a simulation study.
MedLine Citation:
PMID:  8210815     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In cancer studies, the aim of phase I clinical trials is to identify an appropriate dose for experimentation in phase II and III studies. The continual reassessment method (CRM) has been developed recently and presented as the method of choice in the design and analysis of such phase I studies. However, to implement the method, some methodological and practical considerations must be addressed. This paper examines, through a simulation study, the sensitivity of CRM both to the initial modelling of the dose-toxicity relationship and the prior. It appears that the performance of CRM can be improved by using vague priors and initial tuning of the model to allow flexibility.
Authors:
S Chevret
Related Documents :
18605475 - The prep statistic as a measure of confidence in model fitting.
15860765 - Increasing the degrees of freedom in existing group randomized trials: the df* approach.
10473845 - On the directionality of cortical interactions studied by structural analysis of electr...
15078495 - On the evolution of statistical methods as applied to clinical trials.
19000965 - A-optimality orthogonal forward regression algorithm using branch and bound.
3298315 - Fluorescence resonance energy transfer measurements of distances in actin and myosin. a...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Statistics in medicine     Volume:  12     ISSN:  0277-6715     ISO Abbreviation:  Stat Med     Publication Date:  1993 Jun 
Date Detail:
Created Date:  1993-11-01     Completed Date:  1993-11-01     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8215016     Medline TA:  Stat Med     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1093-108     Citation Subset:  IM    
Affiliation:
Département de Biostatistique et Informatique Médicale, Hôpital Saint-Louis, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / administration & dosage*,  adverse effects,  toxicity
Bayes Theorem
Bias (Epidemiology)
Clinical Trials, Phase I as Topic* / methods,  standards
Dose-Response Relationship, Drug
Ethics, Medical
Evaluation Studies as Topic
Humans
Logistic Models
Models, Statistical*
Monte Carlo Method
Neoplasms / drug therapy*,  epidemiology
Organizational Objectives
Research Design*
Sensitivity and Specificity
Chemical
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The nephritogenic T lymphocyte response in interstitial nephritis.
Next Document:  On population and individual bioequivalence.